Signing of the strategic cooperation agreement between Taimei Technology and C&R Research. Credit: Taimei Technology / PR Newswire.
Taimei Technology and South Korea’s C&R Research have signed a strategic partnership deal to co-develop an AI-powered clinical trial operations system.
The collaboration aims to enhance the management and design of clinical trials in South Korea through increased automation and intelligent digital infrastructure.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under this agreement, C&R Research will deploy Taimei Technology’s digital platforms and AI agents, including the electronic data capture (EDC) + intelligent data management (iDM) Agent, across several clinical trial projects.
These technologies are set to automate key elements of the process, such as trial design and operational workflows, with an emphasis on data management.
The implementation includes intelligent data capture, governance, AI-generated electronic case report form (eCRF) creation, and automated test case development. This approach seeks to improve productivity and data quality in clinical research settings.
Taimei’s AI Agent matrix supports scenario-based applications across the clinical research life-cycle.
The collaboration integrates Taimei’s AI-driven approach with South Korea’s clinical trial system, aiming to build a smarter research framework through advanced digital tools.
The country is recognised for its established drug development ecosystem and active participation in international clinical trial pipelines.
Industry analysts expect the partnership to accelerate digital transformation within the country’s clinical research landscape.
C&R Research CEO Moon Tae Yoon said: “As clinical trials become increasingly complex, AI-based data management and operational automation are emerging as essential competitive factors. Through this partnership, we will build a more efficient and innovative clinical execution system.”
Taimei Technology chairman Zhao Lu said: “This partnership represents an important opportunity to bring the AI clinical operations experience we have accumulated in global markets into South Korea.
“We look forward to collaborating with more Korean ecosystem partners to continuously drive the intelligent transformation of clinical trials.”
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.